538 results about "Effector" patented technology

The invention belongs to the field of prevention and treatment of tilletia controversa Kuhn, and particularly relates to a tilletia controversa Kuhn effect protein g16561 and application thereof. An amino acid sequence of the Tilletia controversa Kuhn effect protein is shown as SEQ ID NO: 2. The effect protein plays an important role in the process of inhibiting plant defense reaction, and has an interaction relationship with a wheat protein in the process of infecting wheat by Tilletia controversa Kuhn. According to the invention, the pathogenesis of Tilletia controversa Kuhn can be deeply researched, and the excavation of wheat disease-resistant genes and the cultivation of wheat disease-resistant varieties can be promoted.

The present disclosure relates to compositions and methods for reducing expression of MYC gene in a cell. In some embodiments, an expression repressor comprises a targeting moiety that binds a MYC promoter, anchor sequence, or super-enhancer. In some embodiments, the expression repressor comprises an effector moiety that represses transcription or methylates DNA. Systems comprising two expression repressors are also disclosed. The compositions can be used, for example, to treat cancers such as HCC.

The disclosure provides, for example, double stranded DNA (dsDNA) molecules comprising one or more chemically modified nucleobases. In some embodiments, the dsDNA molecule is circular and comprises a first strand and a second strand, wherein the first strand comprises one or more chemically modified nucleobases, and the second strand is free of chemically modified nucleobases. In some embodiments, the dsDNA molecule comprises a promoter sequence and an effector sequence that encodes an effector.

The invention discloses an arabidopsis thaliana RK3 gene and application of S structural domain receptor kinase RK3 coded by the arabidopsis thaliana RK3 gene in improvement of plant disease resistance, and belongs to the technical field of plant genetic engineering. According to the application of the arabidopsis thaliana RK3 gene to improvement of plant disease resistance, the nucleotide sequence of the arabidopsis thaliana RK3 gene is shown as SEQ ID NO.1, the amino acid sequence of S structural domain receptor kinase RK3 coded by the arabidopsis thaliana RK3 gene is shown as SEQ ID NO.2, and further plants are selected from arabidopsis thaliana, oilseed rape, rice, tomatoes, potatoes, peanuts, soybeans, cotton, tobacco, cucumbers, watermelons and the like. The expression of the plant disease resistance comprises infection resistance to wild-type pseudomonas syringae, effector engineering strains thereof and botrytis cinerea. It is clear that the arabidopsis thaliana RK3 gene and the encoded protein thereof can remarkably enhance the infection resistance of plants to various pathogenic bacteria for the first time, disease prevention and control are achieved by activating the autoimmune system of the plants, and an effective path is provided for reducing chemical pesticide application and promoting agricultural green development.

The present disclosure provides one or more engineered gene effectors and systems, compositions, and methods of use thereof, wherein the one or more engineered gene effectors can be used to effect regulation of a target gene in a cell (e.g., an endogenous target gene in a cell). The one or more engineered gene effectors can be operatively coupled to a heterologous endonuclease, such as a CRISPR / Cas protein.

The invention relates to the field of nucleic acid editing, in particular to the technical field of regularly clustered interval short palindromic repeat (CRISPR). In particular, the invention relates to a mutant of a Cas effector protein, a fusion protein comprising the mutant, and nucleic acid molecules encoding the same. The invention also relates to complexes and compositions for nucleic acid editing (e.g., gene or genome editing). The invention also relates to methods for nucleic acid editing (e.g., gene or genome editing) using the proteins or fusion proteins comprising the invention. Compared with a wild type Cas protein, the Cas protein mutant disclosed by the invention has better activity, such as higher cleavage activity, stronger target site recognition capability and higher target sequence editing activity.

The invention relates to tilletia foetida, in particular to a tilletia foetida effect protein TlRlpA and application thereof. The invention provides a Tilletia foetida effect protein, and the amino acid sequence of the Tilletia foetida effect protein is shown as SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6. The effector protein can effectively inhibit programmed death of plant cells induced by BAX, and plays an important role in inhibiting a plant defense reaction process. The invention lays a foundation for deeply researching the pathogenesis of the tilletia foetida, excavating the tilletia foetida-resistant gene of the wheat and developing the tilletia foetida-resistant wheat variety.

The disclosure provides, for example, DNA molecules comprising at least one nucleotide with a macromolecule, small molecule, or reactive handle (e.g., click handle) appended to a phosphorothioate backbone. The disclosure also provides methods for making such DNA molecules, for example using click chemistry. In some embodiments, the DNA molecule comprises a sequence that encodes an effector (e.g., a therapeutic effector).

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

The invention relates to the field of nucleic acid editing, in particular to the technical field of regularly clustered interval short palindromic repeat (CRISPR). In particular, the invention relates to a mutant of a Cas effector protein, a fusion protein comprising the mutant, and nucleic acid molecules encoding the same. The invention also relates to complexes and compositions for nucleic acid editing (e.g., gene or genome editing). The invention also relates to methods for nucleic acid editing (e.g., gene or genome editing) using the proteins or fusion proteins comprising the invention. Compared with a wild type Cas protein, the Cas protein mutant disclosed by the invention has better activity, such as higher cleavage activity, stronger target site recognition capability and higher target sequence editing activity.

The disclosure provides, for example, a DNA molecule comprising a first strand of DNA, wherein the first strand is circular and single stranded over at least 90% of its length, and a second strand of DNA covalently linked to the first strand as described herein. The DNA molecule may comprise an effector sequence encoding a therapeutic effector. In some embodiments, the DNA molecule shows improved conversion to double-stranded DNA relative to a DNA molecule that lacks the second strand.

The disclosure provides, for example, double stranded DNA (dsDNA) molecules comprising one or more chemically modified nucleobases. In some embodiments, the dsDNA molecule is circular and comprises a first strand and a second strand, wherein the first strand comprises one or more chemically modified nucleobases, and the second strand is free of chemically modified nucleobases. In some embodiments, the dsDNA molecule comprises a promoter sequence and an effector sequence that encodes an effector.

The present disclosure relates to enzymes, compositions and methods for performing conditional homologous recombination of a targeted DNA molecule or genome by using modified proteins comprising nucleic acid DNA binding proteins with protease-conditional recombinase (hereinafter “ProRec”) activity. Namely a new cre recombinase pro enzyme, compositions / kit and sensors comprising the cre recombinase pro enzyme of the present disclosure. Namely, a cre recombinase pro-enzyme, for identifying and quantifying proteolytic activity in a disease or an infection, comprising intein mediated circularization, a flip-excision cassette comprising an output reporter and / or effector protein; a linker sequence cleavable by a protease.

An iRGD-LAMP2B-EGFP fusion protein mediated exosome surface engineering strategy is adopted, through specific recognition of iRGD peptide and integrin alpha v beta 3, corneal neovascularization core lesion cells are actively targeted, the limitation of off-target toxicity of a traditional delivery system is broken through, and a'accurate focus recognition-efficient homing 'targeted delivery normal form is established. Meanwhile, the screened circular RNA with anti-inflammatory and anti-angiogenesis dual activities is used as a core effector molecule, and in combination with an in-situ loading technology of the circular RNA molecule in an exosome parent cell, stable entrapment and targeted release of a nucleic acid drug in an exosome cavity are realized, and the problems that the nucleic acid drug is easy to degrade and poor in targeting property are solved; and dual guarantee of function specificity and delivery stability is formed. And a synergistic treatment system of a targeting exosome carrier and bifunctional circular RNA is further constructed, active molecules are accurately delivered to focus cells, and an inflammation microenvironment and an angiogenesis pathway are synchronously regulated and controlled.

The invention discloses a tool for realizing efficient specific gene inhibition in a plant by utilizing a SunTag system of CRISPR-dCas9 (clustered regularly interspaced short palindromic repeats-das9). According to the method, gRNA near a transcription start site of a targeted target gene is designed, dCas9 and scFv-GFP are accurately recruited to a target site by using a SunTag system, the transcription start process of RNA polymerase II is interfered, and the expression of the target gene is remarkably inhibited. In view of relatively high activity of the system in a plant rdr6 mutant, an artificial miR-RDR6 fragment is further introduced into a vector and is used for inhibiting expression of RDR6 in a wild plant, so that the applicability and functionality of the system are expanded. Compared with a traditional method depending on a plant endogenous effector, the method has the advantages that dependence on endogenous regulatory factors is avoided, the specificity and safety of gene inhibition are remarkably improved, and the method can be used for plant genetic function research and character improvement.

The invention discloses an IV-type secretory effect protein recognition method and system based on multi-modal information, and belongs to the technical field of bioinformatics and secretory protein recognition. The method comprises the following steps: firstly, extracting amino acid residue characteristics of protein by using a protein language model, and constructing a spatial adjacency graph of the protein by using a three-dimensional structure predicted by a protein structure prediction model; respectively extracting sequence features and structural features of the protein through a deep sequence module and a hierarchical graph module; meanwhile, a contrast learning module is introduced to realize cross-modal alignment of the same protein in a potential space; and performing bidirectional interaction on the sequence features and the structural features by using a cross attention module to obtain joint features, and finally outputting a classification result after nonlinear transformation by a gating linear unit for predicting the IV-type secretion effect protein. According to the invention, efficient coordination of sequence and structure bimodal information is realized, and the identification accuracy of the IV-type secretory effect protein is remarkably improved.

The present invention generally relates to tRNA-based effector molecules for use in inserting missense mutations into the open reading frame (ORF) of a gene, e.g., for the treatment of repetitive sequence amplification diseases.

Provided herein are compositions, systems, and methods for the creation, identification, and characterization of effector domains for activating and silencing gene expression. In particular, a high-throughput system for discovering and characterizing effector domains is provided.

The invention discloses a diaphorina citri effector protein DcPDI1 and an application thereof. The amino acid sequence of the diaphorina citri effector protein DcPDI1 is as shown in SEQ ID NO. 1, and the nucleotide sequence of the diaphorina citri effector protein DcPDI1 is as shown in SEQ ID NO. 2. After the diaphorina citri DcPDI1 is knocked out, the egg laying amount and the developmental duration of the diaphorina citri are remarkably reduced, and it is indicated that the DcPDI1 plays an important role in growth and development of the diaphorina citri. The diaphorina citri effect protein DcPDI1 can be a new molecular target spot, plays a key role in activating defensive response of host plants and helping diaphorina citri to eat, and provides a new insight for a molecular mechanism of interaction between diaphorina citri and plants.

Compositions are provided for transient transcriptional modulation of genes through delivery of RNA molecules encoding site-specific DNA binding molecules linked to transcriptional modulation domains, as well as methods for treating or preventing a disease or disorder, including a cancer, infectious disease, or immunological disease.

To provide a method for determining the presence or absence of a target nucleic acid molecule in a sample.SOLUTION: CLAIMS What is claimed is: 1. A method of amplifying a target nucleic acid molecule in a sample, comprising: a) an effector complex comprising a Type III CRISPR-associated effector protein (Cas) and at least one CRISPRRNA (crRNA) that binds to the target nucleic acid molecule; and b) means for directly or indirectly determining the level of cyclic oligoadenylate (cOA). Providing a sample with a Regularly Interspaced Short Palindromic Repeats (CRISPR) - based ribonucleic acid detection system; incubating the sample under conditions that allow the crRNA to bind to its target nucleic acid molecule; and directly or indirectly determining the level of cyclic oligoadenylate (cOA), wherein an increase in the determined cOA level relative to a control is indicative of the presence of the target molecule in the sample.SELECTED DRAWING: None

The invention relates to a method for controlling a sensor-effector system (10), in which a trajectory (12) of a target (14) to be attacked is predicted. Furthermore, at least one section of a first type of the predicted trajectory (12) is determined, which section is located within the range of an effector (16) of the sensor-effector system (10). A hit probability of the effector (16) is determined for different points along the at least one section of the first type. In addition, at least one section of a second type of the predicted trajectory (12) is determined (112), which section overlaps with a field of view of a sensor (18) of the sensor-effector system (10). With regard to the sensor (18), a quality of visibility at different points of the at least one section of the second type is then determined. Along a region of the predicted trajectory (12) in which the section of the first type and the at least one section of the second type of the predicted trajectory (12) overlap, a combat point (20) is then selected on the basis of the determined hit probability and on the basis of the determined quality of visibility.

The present disclosure relates generally to (CRISPR) RNA (crRNA) for the precision silencing of transcripts. In some embodiments, the crRNA are enriched for guanosine (G) nucleotides at key spacer positions, which is useful in enhancing the silencing efficacy of otherwise inefficient crRNA, thereby expanding the targeting spectrum of Cas13 endonucleases, e.g., Cas13b and Cas13d. In other embodiments, the crRNA comprise a spacer sequence having at least one nucleotide mismatch relative to the target RNA sequence, wherein the target RNA sequence is a wild-type transcript and / or a variant transcript (e.g., a transcript comprising a single nucleotide variant (SNV)). The present disclosure also provides RNA editing systems comprising the crRNA described herein in complex a Cas13 effector protein and a target RNA sequence, methods for the selective targeting of transcripts encoding proteins that are difficult to target, or are not amenable to pharmacological targeting, e.g., oncogenic fusion transcripts or oncogenic transcripts comprising single nucleotide variant(s), and methods for the design and selection of potent crRNA.

The invention provides a targeted degradable protein and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the targeted degradation protein is SEQ ID NO.1. When the targeted degradation protein is used for treating breast cancer, target protein degradation can be directly mediated, so that the effect of the target protein is weakened fundamentally, the targeted degradation protein only needs to be combined with the target protein with very strong affinity, specific epitopes do not need to be combined, the design difficulty is low, and the number of adaptive targets is large. Therefore, the targeted degradation protein provided by the invention takes the membrane molecule with high expression of tumor specificity as the effect protein, so that the dual effects of tumor targeting and mediated endocytosis are realized.

Provided herein is a nucleic acid detection system comprising a detection CRISPR system having an effector protein and one or more guide RNAs each designed to bind to corresponding target molecules that are diagnostic for a tick-borne disease state; and an RNA-based masking construct. In some embodiments, the detection system of may comprise i) two or more CRISPR systems, each CRISPR system comprising an effector protein and a guide RNA designed to bind to a corresponding target molecule that is diagnostic for a tick-borne disease state; and ii) a set of detection constructs, each detection construct comprising a cutting motif sequence that is preferentially cut by one of the activated CRISPR effector proteins. Exemplary tick-borne detectable microbes include Babesia microti, Anaplasma phagocytophilum, and Borrelia miyamotoi.

Provided herein are macromolecules that conditionally induce a cellular effector function (e.g., a biological or therapeutic activity) based on the presence of a disease signature ligand, compositions comprising the same, and methods of using the same.

Mutations in oncogenes and tumor suppressor factors contribute to the development and progression of cancer. This disclosure describes compounds and methods for restoring DNA-binding affinity of p53 mutants, as well as their use in diagnostic assays to guide the treatment of subjects with said compounds for cancer. The compounds of this disclosure can bind to mutant p53 and restore the ability of p53 mutants to bind to DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers containing p53 mutations.

The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Aspects of the invention in particular relate to Cpf1 mutants having altered PAM specificity.

An engineered transcriptional modulator (ETM) comprising: (a) at least one epigenetic effector domain; operably linked to (b) an endonuclease.

This invention provides a multispecific antibody with increased in vivo sustainability. [Solution] Structural formula TIFF2026086769000159.tif21128 A multispecific antibody comprising the formula, wherein the antigen-binding fragment (Fab) is serum albumin Fab; R 1 and R 2 These are bioactive effector regions ligated to the N-terminus of Fab, and are linked to either the heavy-chain variable domain or the light-chain variable domain of Fab, respectively; R 3 and R 4 The multispecific antibody is provided, wherein m is a bioactive effector portion linked to the C-terminus of Fab, each linked to either the heavy chain variable domain or the light chain variable domain of Fab; m is 0 or an integer greater than or equal to 1; and n is 0 or an integer greater than or equal to 1.